Skip to main content

Cerebral Vasospasm

2
Pipeline Programs
3
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

NICARDIPINE HYDROCHLORIDEApproved
nicardipine
Unknown Company
oral2024

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
1
NicardipinePhase 4Small Molecule1 trial
Active Trials
NCT01996436Terminated92Est. Aug 2024
Vesalio
VesalioTX - Dallas
2 programs
NEVA VSN/A1 trial
NeVa VSN/A1 trial
Active Trials
NCT06893588Not Yet Recruiting200Est. Mar 2027
NCT03611790Completed30Est. May 2021
Genomics
GenomicsUK - Oxford
1 program
Identification of Novel Molecular Markers for VasospasmN/A1 trial
Active Trials
NCT02389634Completed50Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Temple TherapeuticsNicardipine
VesalioNEVA VS
VesalioNeVa VS
GenomicsIdentification of Novel Molecular Markers for Vasospasm

Clinical Trials (4)

Total enrollment: 372 patients across 4 trials

The Intra-arterial Vasospasm Trial

Start: Aug 2016Est. completion: Aug 202492 patients
Phase 4Terminated

Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts

Start: Apr 2025Est. completion: Mar 2027200 patients
N/ANot Yet Recruiting

Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)

Start: Dec 2018Est. completion: May 202130 patients
N/ACompleted
NCT02389634GenomicsIdentification of Novel Molecular Markers for Vasospasm

Identification of Novel Molecular Markers for Vasospasm

Start: Sep 2010Est. completion: Oct 201950 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.